---
layout: default
title: Bupivacaine
parent: 僅模型預測 (L5)
nav_order: 51
evidence_level: L5
indication_count: 4
---

# Bupivacaine
{: .fs-9 }

證據等級: **L5** | 預測適應症: **4** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Bupivacaine: From Local Anesthesia to Acrodermatitis Chronica Atrophicans

## One-Sentence Summary

Bupivacaine is a long-acting amide-type local anesthetic widely used for regional anesthesia and perioperative pain management. The TxGNN model predicts it may be effective for **Acrodermatitis Chronica Atrophicans (ACA)**, a late-stage cutaneous manifestation of Lyme disease. However, there are currently **0 clinical trials** and **0 publications** specifically supporting this direction, placing this prediction at the lowest possible evidence level.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Local / regional anesthesia and pain management |
| Predicted New Indication | Acrodermatitis Chronica Atrophicans |
| TxGNN Prediction Score | 99.23% |
| Evidence Level | L5 |
| Philippines Market Status | ✗ Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available from the Evidence Pack. Based on widely established pharmacology, Bupivacaine is a long-acting amide-type local anesthetic that acts primarily by blocking voltage-gated sodium channels (Nav1.x), thereby preventing depolarization and inhibiting the propagation of action potentials along nerve fibers. It is most commonly used for epidural analgesia, spinal anesthesia, and peripheral nerve blocks.

Acrodermatitis Chronica Atrophicans (ACA) is a progressive, late-stage skin complication of Lyme disease driven by persistent *Borrelia burgdorferi* infection. Its core pathology involves Th1-dominant cellular immune activation, chronic pro-inflammatory cytokine signaling (IL-6, TNF-α), and eventually dermal fibrosis. Some in vitro evidence suggests local anesthetics can suppress neutrophil migration and reduce cytokine release; however, these effects require locally high drug concentrations (>1 mM) that cannot be achieved at infected skin tissue through systemic administration. Critically, Bupivacaine has no known antibacterial activity against *Borrelia* species, leaving the infectious driver of ACA entirely unaddressed.

The mechanistic connection between sodium channel blockade and the immune-driven, infection-sustained pathology of ACA is extremely weak. The TxGNN model's high score most likely reflects indirect graph-level connectivity within the knowledge graph (e.g., shared inflammatory pathway nodes) rather than a direct or therapeutically actionable pharmacological relationship. No preclinical or clinical data currently supports this repurposing hypothesis.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

Currently no related literature available.

---

## Philippines Market Information

Bupivacaine currently has **no active product registrations** in the Philippines (market status: Not Marketed; total authorized products on record: 0). No authorization table can be generated.

---

## Safety Considerations

Please refer to the package insert for safety information.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
This prediction rests entirely on TxGNN knowledge graph model output (Evidence Level L5) with no supporting clinical trials, observational studies, or published literature of any kind. The mechanistic link between Bupivacaine's sodium channel blocking action and the infection-driven, fibrotic immunopathology of ACA is extremely tenuous, and no preclinical proof-of-concept data exists to justify advancing this hypothesis.

**To proceed, the following is needed:**
- Mechanism of action (MOA) data from DrugBank to formally assess pathway overlap with ACA pathophysiology
- Philippines FDA package insert (or equivalent) to populate key warnings and contraindications before any safety screening can begin
- Preclinical proof-of-concept data demonstrating Bupivacaine's effect in *Borrelia*-driven or fibrotic skin inflammation models
- Drug interaction profiling, particularly given Bupivacaine's known cardiac and CNS toxicity profile
- Clarification on the feasibility of a drug delivery route capable of achieving therapeutic concentrations in affected skin tissue without systemic toxicity
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

